Irbesartan Comp Hexal (Hydrochlorothiazide, Irbesartan)

Irbesartan selectively blocks the AT1 receptor, preventing angiotensin II from causing vasoconstriction and aldosterone release. This leads to relaxation of blood vessels and reduced sodium retention. When combined with hydrochlorothiazide, which promotes diuresis, the overall effect is a greater reduction in blood pressure.

The specific dose of Irbesartan Comp Hexal is determined by the prescribing clinician based on the patient’s blood‑pressure profile, renal function, and other individual factors. Healthcare professionals should follow local prescribing guidelines and adjust the regimen as needed.

Irbesartan Comp Hexal is contraindicated in pregnancy because angiotensin‑II receptor blockers can cause fetal toxicity. Safety during breastfeeding has not been established, so the product should be avoided unless the benefits clearly outweigh the risks and a healthcare professional advises otherwise.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with single‑agent ARBs or thiazide diuretics, the combination offers additive blood‑pressure reduction, often allowing lower doses of each component and simplifying therapy. It may be preferred when monotherapy does not achieve target pressure, but clinicians must consider individual tolerability and potential drug interactions.

The product should be stored at temperatures below 25 °C, in its original container, protected from moisture and direct sunlight. Keep the medication out of reach of children and avoid storing in bathrooms or other humid environments.

Irbesartan Comp Hexal is taken orally, usually once daily, with or without food, as directed by a healthcare professional. The tablet should be swallowed whole with a glass of water and not crushed or chewed unless specifically instructed.

Serious risks include severe hypotension, acute kidney injury, hyperkalemia, and rare but life‑threatening allergic reactions such as anaphylaxis. Patients should be monitored for signs of these conditions, especially during the initial treatment period or when other interacting drugs are used.

The medication is contraindicated in patients with known hypersensitivity to irbesartan, hydrochlorothiazide, or any component of the formulation. It should also be avoided in pregnant women, individuals with severe renal impairment, and those taking aliskiren if they have diabetes.